Millennium Management
DSGN icon

Millennium Management’s Design Therapeutics DSGN Stock Holding History

Millennium Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-34,700
Closed -$200K – 6205
2023
Q1 		$200K Sell
34,700
-35,600
-51% -$266K ﹤0.01% 5168
2022
Q4 		$721K Buy
70,300
+30,300
+76% +$411K ﹤0.01% 4450
2022
Q3 		$669K Buy
+40,000
New +$796K ﹤0.01% 4700

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management's DSGN Position: Q1 2026 in Review

Millennium Management reduced its Design Therapeutics (DSGN) stake by 40% in Q1 2026, selling an estimated $728K and leaving 108,928 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4287.

Millennium Management first reported a position in DSGN in Q1 2021 and has held it in 15 quarters since. The position peaked at $7.57M in Q1 2021. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Millennium Management held 108,928 shares of Design Therapeutics worth $1.16M as of Q1 2026.
  • Millennium Management sold 71,938 Design Therapeutics shares in Q1 2026, an estimated $728K.
  • Design Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4287 holding.
  • Millennium Management first reported a position in Design Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Millennium Management's Design Therapeutics position peaked at $7.57M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.